LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Wins Court Order, Halting $200 Million Trulicity Rebate Fraud
Eli Lilly and Company secured a federal court order against pharmacy groups in Florida and Tennessee for an alleged $200 million fraud scheme. The network...
Eli Lilly and NVIDIA back Abridge to build medical AI operating system
Eli Lilly and NVIDIA are partnering with healthcare AI firm Abridge to develop a foundational AI model for medicine. The New York-announced collaboration aims...
Eli Lilly's Ebglyss Gets FDA Nod for Less Frequent Eight-Week Dosing
The U.S. Food and Drug Administration (FDA) approved a new maintenance dosing schedule for Eli Lilly's EBGLYSS (lebrikizumab-lbkz). This approval targets...
Eli Lilly enters vaccine market for $3.8B, diversifying beyond obesity drugs
Eli Lilly is entering the infectious disease market by acquiring three vaccine companies for a combined $3.83 billion. This strategic expansion diversifies a...
Eli Lilly strikes $1B AlzeCure deal, expanding Alzheimer’s pipeline
Eli Lilly and Company signed a global licensing agreement with Swedish biotech AlzeCure Pharma. The deal focuses on Alzstatin ACD680, a preclinical program for...
🟢 Eli Lilly and Company is trading 3.4% up today after positive late-stage obesity drug data
Eli Lilly and Company is trading 3.4% up at $1,170.00 after releasing highly positive late-stage clinical data for its next-generation obesity drugs presented...
🟢 Eli Lilly surges 4.4% after presenting highly positive Phase 3 data for new obesity drugs
Eli Lilly and Company (LLY) is trading at $1181.00 (+4.4%) in pre-market sessions, driven by the release of highly positive new clinical data for its...
🟢 Eli Lilly and Company is trading 3.24% up today on obesity franchise momentum and strong institutional demand
Eli Lilly and Company is trading 3.24% up at $1,161.70 on continued momentum in its obesity and diabetes franchise and strong institutional demand. • Renewed...
🟢 Eli Lilly and Company is trading 5.2% up today on obesity drug enthusiasm and strong institutional demand
Eli Lilly and Company is trading 5.2% up at $1135.25 following fresh enthusiasm around its obesity and diabetes franchise and evidence of strong institutional...
Eli Lilly Surges 4.6% on Weight-Loss Drug Euphoria and Big-Money Buying — But Can the Stock Keep Outrunning Its Own Hype?
Shares of Eli Lilly jumped 4.6% to $1,127.99 on June 4, snapping a week-long slide that saw the stock drop from $1,126.80 to $1,064.15 in just five sessions....
🟢 Eli Lilly is trading 4.6% up today on a new $1.9B genetic medicine deal and a Weight Watchers partnership
Eli Lilly and Company is trading 4.6% up at $1127.99 following the announcement of a major research partnership and expanded access for its weight-loss drug...
🟢 Eli Lilly and Company is trading 4.5% up today on GLP-1 optimism and institutional dip-buying
Eli Lilly and Company is trading 4.5% up at $1126.80 following strong premarket interest and persistent optimism surrounding its GLP-1 obesity and diabetes...
Eli Lilly Halves €2.3B German Plant Investment, Citing Healthcare Reforms
Eli Lilly is halving its planned €2.3 billion investment in a new manufacturing facility in Alzey, Germany. The company will reduce the number of projected...
Eli Lilly signs $1.9B RNA editing deal, targeting kidney disease
Eli Lilly signed a research and licensing agreement with Ascidian Therapeutics to develop genetic medicines for kidney diseases. The total deal value reaches...
Eli Lilly inks $4.2B in Asian drug deals to bolster pipeline
Eli Lilly and Company signed two significant licensing agreements in Asia on June 1, 2026. The company partnered with China’s Haisco Pharmaceutical in a...
Eli Lilly signs $3 billion Haisco deal to boost drug discovery
Eli Lilly partnered with Chinese drugmaker Haisco Pharmaceutical to develop innovative medicines across multiple therapeutic areas. The collaboration focuses...
Eli Lilly cuts lung cancer recurrence risk 83% in landmark Retevmo trial
Eli Lilly reported that its targeted therapy Retevmo significantly improved outcomes in the Phase 3 LIBRETTO-432 trial. The drug reduced the risk of disease...
Eli Lilly showcases Foundayo data, beating oral semaglutide in weight loss
Eli Lilly and Company will present new cardiometabolic data at the American Diabetes Association's 86th Scientific Sessions from June 5-8. The presentations...
Eli Lilly Challenges Pfizer, Reporting Positive Bladder Cancer Drug Data
Eli Lilly presented Phase 1 trial results for its antibody-drug conjugate LY4052031 at the ASCO Annual Meeting. The drug treats advanced or metastatic...
🔴 LLY is trading 3% down today on profit-taking after obesity-drug reimbursement wins
LLY is trading 3% down at $1092.74 as investors lock in gains following a sharp rally driven by positive obesity-drug developments. • The pullback comes after...